Home › Mercks Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection
 

Keywords :   


Mercks Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection

2014-04-11 07:00:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. Clinical Findings Support Initiation of C-EDGE Phase 3 Program WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced interim results from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of an all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection (GT1). Language: English Contact: MerckMedia Contacts:Caroline Lappetito, 267-305-7639Sarra Herzog, 201-669-6570orInvestor Contacts:Carol Ferguson, 908-500-1101Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: activity combination patients therapy

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Eastern North Pacific Tropical Weather Outlook
20.05Atlantic Tropical Weather Outlook
20.05Farm Progress America, May 20, 2024
20.05Farm Progress America, May 20, 2024
20.05Nielsen launches The Media Distributor Gauge
20.05Minerva AI Companion enhances the TV viewing experience
20.05Ryanair profits surge after fares climb by 20%
20.05SES Ethiosat delivering content to 95% of TV homes in Ethiopia
More »